A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration approval to begin a phase I clinical trial to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. The approval clears the way for Kachlany’s company, Actinobac Biomed, to begin the trial in patients who have relapsed or refractory leukemia or lymphoma. Their experimental drug, Leukothera, has additionally proven effective in treating autoimmune diseases in animals, and Actinobac is also developing its use for that purpose. To read the full story.